Trial Profile
A Randomized, Open Label, Parallel-Group Study to Estimate Bioavailability and to Assess the Pharmacokinetic Profile, Safety and Tolerability of GSK933776 Administered by Subcutaneous or Intramuscular Injection Relative to Intravenous Administration to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs GSK 933776 (Primary) ; GSK 933776 (Primary)
- Indications Alzheimer's disease; Dry age-related macular degeneration
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 25 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 May 2014 Planned End Date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
- 23 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.